ArticleHeliyon2024
Overexpression of C1orf74 predicts poor outcome and promote cervical cancer progression.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer (CC), which ranks among the four most common cancers in women, is a leading cause of both illness and death globally. It's urgent to identify a new biomarker to elucidate the potential mechanisms underlying the progression of CC. Here, we screened the differentially expressed genes (DEGs) in the Cancer Genome Atlas database (TCGA) and selected Chromosome 1 open reading frame 74 (C1orf74) for further investigation. C1orf74 levels were elevated, indicating a link to poor prognosis. Higher expression of C1orf74 was significantly related to clinical stage, T stage, histological type and survival status. Functional enrichment analysis indicated that C1orf74 is likely associated with the MAPK signaling pathway. Moreover, we found that C1orf74 was correlated with multifarious immune cell infiltration. Finally, the knockdown of C1orf74 significantly inhibited the growth of CC in vitro. In conclusion, C1orf74 promotes CC proliferation and progression, is closely associated with poor prognosis, and plays a role in the tumor immune microenvironment. The research indicates that C1orf74 is important for treating CC and may help develop new strategies to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.